Latest Biotech News

Eli Lilly moved again in genetic medicine with an all-cash acquisition of Engage Biologics, paying up to $202 million for a non-viral DNA delivery platform. Engage’s preclinical...

Parabilis filed for an initial public offering days after securing a major strategic pact with Regeneron to pursue antibody–peptide conjugates aimed at historically difficult intracellular...

Immunovant’s IMVT-1402 generated a market-moving early readout in difficult-to-treat rheumatoid arthritis. The company disclosed “compelling” initial Phase IIb open-label results for patients with...

The sector’s diagnostics focus intensified with additional evidence that molecular assays are being broadened across the cancer care continuum. Personalis’ Medicare expansion for NeXT Personal in...

U.S. Congressman Neal Dunn introduced the Enhancing CLIA Act of 2026, aiming to update oversight provisions for laboratory-developed tests after a 2025 court decision that treated LDTs as medical...

A multi-agent AI system described as Robin demonstrated an end-to-end workflow for experimental biology, including hypothesis generation, experiment design, and data analysis—then closed the loop...

The WHO declared the ongoing Ebola outbreak caused by the Bundibugyo species a public health emergency of international concern, citing expanding suspected clusters and significant uncertainty...

New evidence in obesity and cardiometabolic risk centered on oral semaglutide’s effects across multiple endpoints in overweight and obese populations. A systematic review and meta-analysis...

Guardant Health secured FDA approval for its upgraded Guardant360 Liquid CDx, a blood-based comprehensive genomic test designed to expand tumor profiling for patients with advanced cancer. The new...

Executives and an academic expert told a biotech forum that recent turmoil and personnel changes at the FDA are raising anxiety among rare-disease drug developers. At the STAT Breakthrough Summit...

Eli Lilly agreed to buy Engage Biologics in a deal worth up to $202 million to expand its non-viral DNA delivery capabilities for genetic medicines. Engage’s preclinical platform, dubbed...

Parabilis Medicines filed for an initial public offering after inking a strategic collaboration with Regeneron focused on Helicon-based antibody-peptide conjugates. Parabilis’ IPO filing follows a...

Oorja Bio launched with $30 million in seed funding to develop a novel approach for idiopathic pulmonary fibrosis, a disease with limited treatment options. The new company’s strategy focuses on...

Immunovant shares jumped after the company disclosed early Phase 2b findings for IMVT-1402, a next-generation FcRn inhibitor in difficult-to-treat rheumatoid arthritis (D2T RA). The study includes...

Relay Therapeutics reported a Phase 2 efficacy signal for zovegalisib (RLY-2608) in PIK3CA-driven vascular anomalies, a group of rare disorders with limited approved options. The company said the...

Diasorin is accelerating US molecular diagnostics and point-of-care positioning, disclosing plans to raise its US molecular market share over the next four years. At an investor day, the company...

The WHO declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo a public health emergency of international concern, reflecting the fast escalation and geographic spread into...

Qiagen said it is working with Nvidia to integrate accelerated computing and Nvidia BioNeMo into its Qiagen Digital Insights curated biomedical knowledgebases. The company said the goal is to...

FDA has approved Guardant Health’s upgraded Guardant360 Liquid CDx, extending the same companion-diagnostic indications from the earlier test to a broader genomic footprint. The new blood-based...

Immunovant surged after releasing early but “compelling” Phase 2b data for IMVT-1402, its next-generation FcRn inhibitor in difficult-to-treat rheumatoid arthritis (D2T RA). The open-label 16-week...